? Bioanalytical Core The Bioanalytical Core Laboratory will provide state of the art and innovative bioanalytical expertise and techniques for the quantification of drugs and their metabolites, endogenous chemicals and other molecules of biological significance in new collaborative studies with the other cores in the center and all the funded drug abuse biomedical researchers at this and neighboring universities. These analyses will provide the expertise to perform new and innovative research and to enhance currently funded research projects in ways not anticipated at the time of their application submission. This core will accomplish these goals by making available reliable, validated mass spectrometric analysis of biological and non-biological materials for new projects as well as for NIH sponsored and other researchers studying the mechanism of action of abused substances and addiction. The laboratory will develop methods focused on the identification and quantification in biologic specimens of drugs and/or drug metabolites, such as cocaine, nicotine, cotinine, tetrahydrocannabinol (THC), and, natural occurring psychoactive compounds such as nuciferine, apomorphine and mitragynine, as well as physiologically active small endogenous molecules and/or their metabolites such as anandamide, other endocannabinoids, prostamides and ceramide metabolites of sphingomelingolipids. These analyses will enhance the pharmacological studies of drugs of abuse by providing pharmacokinetic analysis including drug disposition, metabolism and clearance. The Bioanalytical Core will develop novel and innovative techniques for minimum sample preparation to allow rapid isolation and quantification of polar drug metabolites and glucuronide metabolites. We will expand on the breadth of types of small molecules including additional substances of abuse designer drugs (i.e., synthetic opioids, cannabimimetic, and cathinones), and their metabolites, a wider range of endogenous compounds which have similar pharmacological effects as drugs of abuse including endocannabinoids, peptides, lipids and other biological transmitters or signaling compounds. We will also enhance selectivity capabilities with differential ion mobility mass spectrometry (DMS) allowing us to increase our quantification of isobaric compounds, identify metabolites not seen before, and separation of ions of interest from interfering ions. Incorporating micro-extraction/sample preparation technologies and/or two-dimensional chromatographic separations combined with mass spectrometry (MS), DMS selectivity capability, will provide new dimensions to the research proposed of all drug abuse researchers on this campus and those in our neighboring institutions.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
2P30DA033934-06
Application #
9572670
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
2024-03-31
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Donvito, Giulia; Nass, Sara R; Wilkerson, Jenny L et al. (2018) The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology 43:52-79
Wolstenholme, Jennifer T; Bowers, M Scott; Pais, Alexander B et al. (2018) Dietary Omega-3 Fatty Acids Differentially Impact Acute Ethanol-Responsive Behaviors and Ethanol Consumption in DBA/2J Versus C57BL/6J Mice. Alcohol Clin Exp Res :
Hermes, Douglas J; Xu, Changqing; Poklis, Justin L et al. (2018) Neuroprotective effects of fatty acid amide hydrolase catabolic enzyme inhibition in a HIV-1 Tat model of neuroAIDS. Neuropharmacology 141:55-65
Mischel, Ryan A; Dewey, William L; Akbarali, Hamid I (2018) Tolerance to Morphine-Induced Inhibition of TTX-R Sodium Channels in Dorsal Root Ganglia Neurons Is Modulated by Gut-Derived Mediators. iScience 2:193-209
Shin, Myungsun; Snyder, Helena W; Donvito, Giulia et al. (2018) Liposomal Delivery of Diacylglycerol Lipase-Beta Inhibitors to Macrophages Dramatically Enhances Selectivity and Efficacy in Vivo. Mol Pharm 15:721-728
Gonek, Maciej; McLane, Virginia D; Stevens, David L et al. (2018) CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward. Brain Behav Immun 69:124-138
Curry, Zachary A; Wilkerson, Jenny L; Bagdas, Deniz et al. (2018) Monoacylglycerol Lipase Inhibitors Reverse Paclitaxel-Induced Nociceptive Behavior and Proinflammatory Markers in a Mouse Model of Chemotherapy-Induced Neuropathy. J Pharmacol Exp Ther 366:169-183
Cooper, Ziva D; Poklis, Justin L; Liu, Fei (2018) Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073. Neuropharmacology 134:92-100
Akbarali, Hamid I; Dewey, William L (2017) The gut-brain interaction in opioid tolerance. Curr Opin Pharmacol 37:126-130
Dempsey, Sara K; Poklis, Justin L; Sweat, Kacie et al. (2017) Acute Toxicity From Intravenous Use of the Tricyclic Antidepressant Tianeptine. J Anal Toxicol 41:547-550

Showing the most recent 10 out of 93 publications